A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors by Aurora Norman, Mahesh Seetharam, Jacob Allred, Jianping Kong, Mateusz Opyrchal, Wen Wee Ma, Yanyan Lou, Grace K. Dy, Amit Mahipal, S. John Weroha, Andrea E. Wahner Hendrickson, Joel M. Reid, Alex A. Adjei

Get full text

Lestaurtinib’s antineoplastic activity converges on JAK/STAT signaling to inhibit treatment naïve and therapy resistant forms ovarian cancer by Esther P. B. Rodman, Michael J. Emch, Xiaonan Hou, Archit Bajaj, Nicole A. Pearson, August J. John, Yamillie Ortiz, Adam D. Bass, Saloni Singh, Gustavo Baldassarre, Scott H. Kaufmann, S. John Weroha, John R. Hawse

Get full text

Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma by Xiaonan Hou, Valentina Zanfagnin, Conway Xu, Erik Jessen, Yuanhang Liu, Chen Wang, Yajue Huang, Shaun D. Fontaine, Daniel V. Santi, Gerardo Colon-Otero, Sarah E. Gill, Gretchen E. Glaser, Kristina A. Butler, Jamie N. Bakkum-Gamez, Sean C. Dowdy, Ann L. Oberg, Melissa C. Larson, Hunter J. Atkinson, Laura N. Duffield, Kevin L. Peterson, Scott H. Kaufmann, S. John Weroha

Get full text

Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity by Rachel M. Hurley, Jill M. Wagner, Arun Kanakkanthara, Annapoorna Venkatachalam, Aaron M. Deisinger, Cristina Correia, Paula A. Schneider, Kevin L. Peterson, Elaine P. Macon, Ethan P. Heinzen, Kumar Sanjiv, Xiaonan Hou, Marc A. Becker, Matthew J. Maurer, Melissa C. Larson, Elizabeth M. Swisher, Hu Li, Ann L. Oberg, S. John Weroha, Ulrika Warpman Berglund, Thomas Helleday, Scott H. Kaufmann, Andrea E. Wahner Hendrickson

Get full text